|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| Information provided by: | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| ClinicalTrials.gov Identifier: | NCT00004554 |
Purpose
This study will examine depressed alcoholic outpatients to assess whether combining naltrexone (Revia) and sertraline (Zoloft) will result in greater reductions in both drinking and depression over either medication alone or placebo. A secondary aim is to determine whether certain patient features will predict response to sertraline, naltrexone or the combination of the two drugs. Subjects will be randomized into treatment groups for 16 weeks. The followup phase includes two visits at 6 and 9 months after treatment.
| Condition | Intervention | Phase |
|
Alcoholism Depression |
Drug: naltrexone (Revia) Drug: sertraline (Zoloft) |
Phase IV |
| MedlinePlus related topics: | Alcoholism Depression |
| ChemIDplus related topics: | Sertraline hydrochloride Sertraline Naltrexone Naltrexone hydrochloride Ethanol |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study |
| Official Title: | Sertraline for Alcohol Dependence and Depression |
Eligibility
| Ages Eligible for Study: | 21 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | NIAAAPET09544 |
| First Received: | February 4, 2000 |
| Last Updated: | December 18, 2007 |
| ClinicalTrials.gov Identifier: | NCT00004554 |
| Health Authority: | United States: Federal Government |
|
|
|
|